The role of fluoroquinolones in tuberculosis today

Drugs

Volumn 61, Issue 1, 2001, Pages 9-18

  Berning, S E ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOSERINE; CYTOCHROME P450; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN;

CENTRAL NERVOUS SYSTEM DISEASE; CROSS RESISTANCE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION PREVENTION; LIVER TOXICITY; LONG TERM CARE; MALABSORPTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; RASH; REVIEW; TUBERCULOSIS;

EID: 0035138527     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00002     Document Type: Review

References (50)

1. Global surveillance for antituberculosis-drug resistance, 1994-1997
2. Pitfalls in the care of patients with tuberculosis: Common errors and their association with the acquisition of drug resistance
3. Fluoroquinolones: A new treatment for tuberculosis?
4. Activity of quinolones against mycobacteria
5. In vitro activitics of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis
6. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355)
7. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
8. Sparfloxacin worldwide in vitro literature
9. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against mycobacterium tuberculosis and mycobacterium avium complex
10. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens
11. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis
12. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages
13. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampicin against M. tuberculosis in cultured human macrophages
14. Combined effect of pyrazinamide and ofloxacin within the human macrophage
15. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis
16. Which aminoglycoside of fluoroquinolones is more active against Mycobacterium tuberculosis in mice?
17. Therapeutic effects of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis
18. GyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong
19. Characterization of fluoroquinoloue-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients
20. Treatment of multidrug-resistant tuberculosis
21. Emergence of fluoroquinolone-resistant tuberculosis in New York City
22. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin
23. Ofloxacin and ciprofloxacin in the treatment of mycobacterial infections: Development of resistance and drug interactions
24. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
25. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis
26. Pharmacokinetics and pharmacodynamics of fluoroquinolones
27. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones
28. Tissue penetration of the new quinolones in humans
29. Prospective comparative study of ofloxacin of ethambutol for the treatment of pulmonary tuberculosis
30. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin
31. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum
32. Treatment of tuberculosis and tuberculosis infection in adults and children
33. Chemoprophylaxis of multidrug-resisrant tuberculous infection in HIV-unifected individuals using ciprofloxacin and pyrazinamide: A decision analysis
34. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin
35. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis
36. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis
37. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of tuberculosis
38. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiple resistant pulmonary tuberculosis
39. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin
40. Using therapeutic drug monitoring to dose the antimycobacterial drugs
41. Malabsorption of antituberculous medications by a patient with AIDS
42. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections
43. Levofloxacin in the treatment of M. tuberculosis and non-tuberculous mycobacteria
44. Fluoroquinolone toxicity profile: A review focusing on newer agents
45. Interactions of fluoroquinolones with other drugs: Mechanisms, variability, clinical significance, and management
46. Implications of quinolone pharmacokinetic drug interactions
47. Tuberculosis in children